Cancer Research The Future of Cancer Research: Science and Patient Impact  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 56, 4370-4373, October 1, 1996]
© 1996 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kuehl, W. M.
Right arrow Articles by Bergsagel, P. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kuehl, W. M.
Right arrow Articles by Bergsagel, P. L.

Selective Expression of One c-myc Allele in Two Human Myeloma Cell Lines

W. Michael Kuehl1, Leslie A. Brents, Marta Chesi and P. Leif Bergsagel

National Cancer Institute-Navy Medical Oncology Branch, NIH. Bethesda, Maryland 20889-5105 [W. M. K., L. A. B., M. C.], and Division of Hematology/Oncology, Cornell University Medical College, New York, New York 10021 [P. L. B.]

Chromosomal translocations or DNA rearrangements affecting c-myc occur in almost all murine plasmacytoma and human Burkitt's lymphoma tumors and are associated with a high incidence of exon 2 missense mutations and selective expression of the affected allele. Screening nine multiple myeloma cell lines, we identified no exon 2 missense mutations but did identify two lines with single, silent mutations in exon 1 and exon 2, respectively. Each of these informative multiple myeloma cell lines selectively expresses only one c-myc allele despite the apparent absence of chromosomal translocations or DNA rearrangements affecting c-myc.

1 To whom requests for reprints should be addressed, at National Cancer Institute-Navy Medical Oncology, Naval Hospital. Building 8. Room 5101, Bethesda, MD 20889-5105, Phone: (301) 496-0925; Fax: (301) 496-0047; E-mail: Michael_Kuehl@nih.gov.

Received 6/28/96. Accepted 8/16/96.




This article has been cited by other articles:


Home page
BloodHome page
M. Chesi, L. A. Brents, S. A. Ely, C. Bais, D. F. Robbiani, E. A. Mesri, W. M. Kuehl, and P. L. Bergsagel
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma
Blood, February 1, 2001; 97(3): 729 - 736.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
Y. Shou, M. L. Martelli, A. Gabrea, Y. Qi, L. A. Brents, A. Roschke, G. Dewald, I. R. Kirsch, P. L. Bergsagel, and W. M. Kuehl
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma
PNAS, January 4, 2000; 97(1): 228 - 233.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1996 by the American Association for Cancer Research.